Vaxcyte (Nasdaq: PCVX) Q2 loss, Approximately $2.5 Billion cash, trial data
Rhea-AI Filing Summary
Vaxcyte, Inc. reported a second-quarter 2026 net loss of $284.3 million, compared to $166.6 million a year earlier, as it increased investment in its pneumococcal conjugate vaccine (PCV) programs. Research and development expenses were $267.9 million and general and administrative expenses were $34.9 million. Cash, cash equivalents and investments were $2,507.7 million as of June 30, 2026.
The company reported full enrollment of its three adult VAX-31 Phase 3 OPUS trials and a Phase 2 infant study, with topline OPUS-1 noninferiority data expected in the fourth quarter of 2026 and OPUS-2 and OPUS-3 results in the first half of 2027. A Phase 1 study of VAX-A1 for Group A Streptococcus is underway, with topline data anticipated in the second half of 2027. Management highlighted approximately $2.5 billion in cash and investments as supporting planned clinical, manufacturing and commercial-readiness milestones.
Positive
- None.
Negative
- None.
Filing Explained
The filing changes Vaxcyte’s board membership and leaves VAX-A1’s next study stage conditional on a safety review.
Vaxcyte appointed Dr. Moncef Slaoui and Dr. John Markels to replace retiring directors Jacks Lee and Heath Lukatch, changing the composition of the company’s board.
The VAX-A1 Phase 1 study is underway: all Stage 1 participants have received the first of two planned doses, while Stage 2 is conditional on the Data Safety Monitoring Board’s approval after reviewing unblinded Stage 1 safety and tolerability data.
For VAX-31, the company is planning a manufacturing-consistency study as the final Phase 3 study intended to enable a Biologics License Application submission; the filing describes that study as planned rather than completed.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash, cash equivalents and investments: $2,507.7 million
Net loss: $284.3 million
Research and development expenses: $267.9 million
+5 more
8 metrics
Cash, cash equivalents and investments
$2,507.7 million
As of June 30, 2026
Net loss
$284.3 million
Three months ended June 30, 2026
Research and development expenses
$267.9 million
Three months ended June 30, 2026
General and administrative expenses
$34.9 million
Three months ended June 30, 2026
Total assets
3,138,154 thousand
As of June 30, 2026
Total stockholders' equity
2,757,942 thousand
As of June 30, 2026
Weighted-average shares outstanding
144,494,106
Basic and diluted, three months ended June 30, 2026
Adults dosed in VAX-31 Phase 3 OPUS trials
6,191
Total adults enrolled across OPUS-1, OPUS-2 and OPUS-3
Key Terms
pneumococcal conjugate vaccines (PCV), noninferiority trial, Biologics License Application (BLA), Data Safety Monitoring Board, +1 more
5 terms
pneumococcal conjugate vaccines (PCV) medical
"across our adult and infant pneumococcal conjugate vaccines (PCV) franchise"
noninferiority trial medical
"The OPUS-1 Phase 3 pivotal, noninferiority trial, in which 4,049 participants"
A noninferiority trial is a clinical study designed to show that a new treatment or drug is not meaningfully worse than an existing standard by more than a pre-set limit. Investors care because a successful noninferiority result can clear the way for approval or market entry when the new option offers other advantages—such as lower cost, easier use, or fewer side effects—much like proving a cheaper car performs nearly as well as a pricier model.
Biologics License Application (BLA) regulatory
"would enable our planned Biologics License Application (BLA) submission"
A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.
Data Safety Monitoring Board medical
"proceed contingent upon the Data Safety Monitoring Board’s approval"
A data safety monitoring board is a group of experts who regularly review information from a research or testing process to ensure it is safe and ethical. Think of them as watchdogs that watch over ongoing projects to protect participants and ensure everything is proceeding correctly. Their oversight helps maintain trust and safety, which is important for investors who want to see responsible management and reliable results.
cell-free protein synthesis platform technical
"through XpressCF®, its cell-free protein synthesis platform"
Earnings Snapshot
Net loss: $284.3 million
quarter ended June 30, 2026
Net loss
$284.3 million
compared to $166.6 million for the same period in 2025
Research and development expenses
$267.9 million
compared to $194.2 million for the same period in 2025
General and administrative expenses
$34.9 million
compared to $32.0 million for the same period in 2025
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Vaxcyte (PCVX)'s key financial results for Q2 2026?
Vaxcyte reported a Q2 2026 net loss of $284.3 million, versus $166.6 million in Q2 2025. R&D expenses were $267.9 million and G&A expenses were $34.9 million, reflecting higher spending on PCV development and growing headcount.
How much cash does Vaxcyte (PCVX) have as of June 30, 2026?
As of June 30, 2026, Vaxcyte had cash, cash equivalents and investments of $2,507.7 million, described as approximately $2.5 billion. Management stated this strong balance sheet supports planned clinical, manufacturing and commercial-readiness activities across its vaccine programs.
What is the status of Vaxcyte (PCVX)'s VAX-31 adult Phase 3 OPUS trials?
All three adult VAX-31 Phase 3 OPUS trials are fully enrolled with 6,191 adults dosed, about 3,500 receiving VAX-31. Topline data from the OPUS-1 pivotal noninferiority trial are expected in Q4 2026, with OPUS-2 and OPUS-3 results in the first half of 2027.
What upcoming clinical milestones did Vaxcyte (PCVX) highlight?
Vaxcyte plans OPUS-1 Phase 3 topline data in Q4 2026, OPUS-2 and OPUS-3 Phase 3 data in first-half 2027, VAX-31 infant Phase 2 data by end of first-half 2027, and VAX-A1 Phase 1 adult topline data in second-half 2027.
What is VAX-A1 in Vaxcyte (PCVX)'s pipeline and how is its Phase 1 study progressing?
VAX-A1 is a prophylactic vaccine candidate for disease caused by Group A Streptococcus. A Phase 1, first-in-human study in healthy adults began in June 2026; Stage 1 participants received the first of two planned doses, with topline data expected in the second half of 2027.
What board changes did Vaxcyte (PCVX) disclose?
Vaxcyte’s board appointed Dr. Moncef Slaoui and Dr. John Markels as new members, replacing Jacks Lee and Heath Lukatch, who retired. The company cited Dr. Slaoui’s and Dr. Markels’ extensive vaccine and pharmaceutical leadership experience.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2026
_____________________________________________
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (650 ) 837-0111
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit Number | Description | |||||||
| 99.1 | Press Release of Vaxcyte, Inc., dated August 5, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| VAXCYTE, INC. | |||||||||||
| Date: | August 5, 2026 | By: | /s/ Andrew Guggenhime | ||||||||
| Andrew Guggenhime President and Chief Financial Officer | |||||||||||
Exhibit 99.1
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027
Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027
Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027
Approximately $2.5 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026
SAN CARLOS, Calif., August 5, 2026 – Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
"With the VAX-31 OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials and the VAX-31 Phase 2 infant study fully enrolled, we expect a series of meaningful clinical study readouts across our adult and infant pneumococcal conjugate vaccines (PCV) franchise over the next 12 months," said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte. "We are on track to deliver the topline data from the OPUS-1 noninferiority trial in the fourth quarter of this year. Following, we expect to announce the results of the OPUS-2 and OPUS-3 trials in the first half of 2027, which along with a manufacturing consistency study, would enable our planned Biologics License Application (BLA) submission and potential U.S. commercial launch."
"With $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, we maintain a strong balance sheet and are well positioned to execute on our planned clinical, manufacturing and commercial-readiness milestones across our PCV development programs," said Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. "As we prepare for the Company’s next phase of growth, we continue to advance our early-stage pipeline, including VAX-A1, a prophylactic vaccine candidate designed to prevent disease caused by Group A Strep, now in a Phase 1 adult study, and VAX-XL, our preclinical, next-generation PCV candidate designed to provide the broadest coverage of any PCV currently in development."
Key Second Quarter and Recent Highlights
PCV Franchise Adult Indication:
Enrollment Completed for Three VAX-31 Adult Phase 3 OPUS Trials; Topline Data from OPUS-1 Expected in Fourth Quarter 2026: All three ongoing VAX-31 Phase 3 clinical trials (OPUS-1, OPUS-2 and OPUS-3) are fully enrolled with 6,191 adults dosed in total, approximately 3,500 of whom received VAX-31. These studies, which were finalized in consultation and alignment with the U.S. Food and Drug Administration (FDA), are designed to generate a broad and robust safety, tolerability and immunogenicity dataset. In addition, the Company is planning a manufacturing consistency study (e.g., a lot-to-lot study) as the final Phase 3 study to enable the submission of the BLA.
•The OPUS-1 Phase 3 pivotal, noninferiority trial, in which 4,049 participants were dosed, is evaluating the safety, tolerability and immune responses of VAX-31 in healthy, pneumococcal-naïve1 U.S. adults aged 50 years and older through direct, head-to-head comparisons with both Prevnar 20® (PCV20) and Capvaxive® (PCV21), the current standard-of-care PCVs, with the objective of establishing a best-in-class profile for VAX-31. The trial is also evaluating the safety, tolerability and immune responses of VAX-31 in a separate cohort of adults aged 18-49.
•The OPUS-2 Phase 3 study, in which 1,390 participants were dosed, is evaluating the safety, tolerability and immunogenicity of VAX-31 when administered either concomitantly with or one month following administration of a licensed seasonal influenza vaccine in healthy, pneumococcal-naïve U.S. adults aged 50 years and older. The results of this descriptive study are intended to inform the design of a potential post-licensure outcomes study that further evaluates VAX-31 in concomitant use with an influenza vaccine and to provide supportive evidence as part of the broader Phase 3 dataset.
•The OPUS-3 Phase 3 descriptive study, in which 752 participants were dosed, is evaluating the safety, tolerability and immunogenicity of VAX-31 in healthy U.S. adults aged 50 years and older who have previously received pneumococcal vaccination, including whether VAX-31 can expand the breadth of protection and boost responses to the serotypes included in the lower-valency pneumococcal vaccines.
Early-Stage Pipeline:
Initiated Phase 1 Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus: In June 2026, the Company announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1, an investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus (Group A Strep or Streptococcus pyogenes), in healthy adults aged 18 to 40 years. All participants enrolled in Stage 1 of the study have received the first of two planned doses. The Stage 2 portion of the study is expected to proceed contingent upon the Data Safety Monitoring Board’s approval following the review of unblinded Stage 1 safety and tolerability data. All participants in the study will be evaluated for safety through six months after receiving the second dose.
The primary objective of this randomized, double-blind, placebo-controlled, dose-escalation, two-stage study is to assess the safety and tolerability of VAX-A1, along with a secondary objective of evaluating initial immunogenicity data, to support potential further advancement. This approach is
1 Pneumococcal-naïve is defined as having no known prior history of IPD or pneumococcal pneumonia, or receipt of any licensed or investigational pneumococcal vaccine.
designed to generate comprehensive initial safety data and provide a foundation for evaluating next steps in the program’s development. Group A Strep remains a major global cause of morbidity and mortality in adults and children and is a leading driver of antibiotic use, underscoring the significant public health burden.
Board of Directors:
Appointment and Retirement of Directors: The Board of Directors has appointed two new members, Dr. Moncef Slaoui and Dr. John Markels, to replace retiring members, Mr. Jacks Lee and Dr. Heath Lukatch. The Company thanks both retiring members for their considerable contributions during their service.
•Dr. Slaoui most recently served as Chief Scientific Advisor of Operation Warp Speed, the U.S. government effort to accelerate the development of COVID-19 vaccines. Prior to that, Dr. Slaoui spent nearly 30 years at GlaxoSmithKline, where he served as a member of the board of directors of GSK plc; Chairman of Pharmaceutical R&D; Chairman of Global R&D, Vaccines and Oncology; and Chairman of Global Vaccines, during which he was directly involved in building the company's vaccine pipeline.
•Dr. John Markels brings over 35 years of leadership experience in the pharmaceutical industry, including a longstanding tenure with Merck where he most recently served as President of Merck Global Vaccines. He has worked across global commercial leadership, strategy and organizational development, as well as manufacturing, development and technology transfer.
Anticipated Program Milestones
Vaxcyte is advancing the clinical development of its pipeline programs with several key milestones anticipated:
VAX-31 Adult Indication
•Announce topline safety, tolerability and immunogenicity data from the OPUS-1 Phase 3 pivotal, noninferiority trial in fourth quarter of 2026.
•Announce safety, tolerability and immunogenicity data from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of 2027.
VAX-31 Infant Indication
•Announce topline safety, tolerability and immunogenicity data from the VAX-31 infant Phase 2 randomized, dose-finding study from both the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027.
VAX-A1
•Announce topline data from the Phase 1 study in adults in the second half of 2027.
Second Quarter 2026 Financial Results
•Cash Position: Cash, cash equivalents and investments were $2,507.7 million as of June 30, 2026, compared to $2,442.6 million as of December 31, 2025.
•Research & Development (R&D) Expenses: R&D expenses were $267.9 million for the three months ended June 30, 2026 as compared to $194.2 million for the same period in 2025. The increase was due primarily to higher development and product manufacturing costs associated with the Company's PCV programs, including for manufacturing activities to support the potential future commercial launches and clinical trial expenses primarily related to the VAX-31 OPUS Phase 3 trials, as well as higher personnel expenses related to the growth in the number of R&D employees.
•General & Administrative (G&A) Expenses: G&A expenses were $34.9 million for the three months ended June 30, 2026 as compared to $32.0 million for the same period in 2025. The increase was due primarily to higher personnel expenses related to the growth in the number of G&A employees.
•Net Loss: For the three months ended June 30, 2026, net loss was $284.3 million, compared to $166.6 million for the same period in 2025.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and vaccine
candidates, including breadth of coverage, the ability to deliver potentially best-in-class vaccines and improve upon the standard-of-care; the design, timing of initiation, progress and expected results of Vaxcyte's clinical trials and regulatory plans; the future commercialization of Vaxcyte’s PCV programs; Vaxcyte’s cash runway; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Readers should not rely upon the information in this press release as current or accurate after its publication date.
# # #
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
Vaxcyte, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Research and development (1) | $ | 267,852 | $ | 194,179 | $ | 580,631 | $ | 342,313 | |||||||||||||||
General and administrative (1) | 34,925 | 32,040 | 67,996 | 64,699 | |||||||||||||||||||
Total operating expenses | 302,777 | 226,219 | 648,627 | 407,012 | |||||||||||||||||||
Loss from operations | (302,777) | (226,219) | (648,627) | (407,012) | |||||||||||||||||||
Other income, net: | |||||||||||||||||||||||
Interest income | 25,755 | 31,073 | 52,365 | 64,008 | |||||||||||||||||||
Other income (expense) | (7,280) | 28,573 | (8,662) | 35,713 | |||||||||||||||||||
Total other income, net | 18,475 | 59,646 | 43,703 | 99,721 | |||||||||||||||||||
Net loss | $ | (284,302) | $ | (166,573) | $ | (604,924) | $ | (307,291) | |||||||||||||||
Net loss per share, basic and diluted | $ | (1.97) | $ | (1.22) | $ | (4.26) | $ | (2.26) | |||||||||||||||
Weighted-average shares outstanding, basic and diluted | 144,494,106 | 136,033,746 | 142,014,171 | 135,863,299 | |||||||||||||||||||
___________________________________________
(1)Amounts include stock-based compensation expense as follows:
Research and development | $ | 22,145 | $ | 20,191 | $ | 42,823 | $ | 36,117 | |||||||||||||||
General and administrative | 19,096 | 16,736 | 36,382 | 31,425 | |||||||||||||||||||
Total stock-based compensation expense | $ | 41,241 | $ | 36,927 | $ | 79,205 | $ | 67,542 | |||||||||||||||
Vaxcyte, Inc.
Summary Consolidated Balance Sheet Data
(in thousands)
June 30, 2026 | December 31, 2025 | ||||||||||
Cash, cash equivalents and investments | $ | 2,507,734 | $ | 2,442,623 | |||||||
Total assets | 3,138,154 | 3,002,717 | |||||||||
Total stockholders' equity | 2,757,942 | 2,685,510 | |||||||||